Assisted by a deep in vivo pharmacological evaluation, here we present, in a proof-of-concept study, the first evidence that dual modulation of CysLT1R/GPBAR1 represents a new armamentarium in NASH pharmacological treatment. Here, CYSLTR1 is linked to metabolic dysfunction-associated steatohepatitis.